Professionals 203 Users Online

Influenza Diagnostics Market

Increasing demand for diagnostic testing has boosted the growth in the influenza diagnostics market

Influenza Diagnostics Market is segmented by Molecular Diagnostic Tests, Traditional Diagnostic Tests, Type of Flu, end-user

Influenza Diagnostics Market Outlook (2023-2033)

Worldwide revenue from the influenza diagnostics market stands at US$ 1.6 Bn in 2022, with the global market estimated to surge ahead at a CAGR of 6.1% to reach a valuation of US$ 3.1 Bn by the end of 2033.

Influenza Diagnostics Market Size (2022)

US$ 1.61 Bn

Projected Market Value (2033)

US$ 3.08 Bn

Global Market Growth Rate (2023-2033)

6.1% CAGR

Market Share of Top 5 Countries


As assessed by Persistence Market Research, traditional diagnostic tests are expected to hold a largest market value of US$ 1.14 Bn by 2023. Overall, influenza diagnostics market sales account for approximately 4.8% revenue share in the global infectious disease diagnostic market, which was valued at around US$ 33.5 Bn at the end of 2022.

Sample Report

FREE Report Sample is Available

In-depth report coverage is now just a few seconds away

Download PDF Get FREE Report Sample

Sales Analysis of the Global Market from 2015 to 2022 Vs Market Outlook for 2023 to 2033 start

The global market for influenza diagnostics recorded a historic CAGR of 5.6% in the last 7 years from 2015 to 2022.

The influenza virus is the infectious disease that causes influenza, also referred to as "the flu." Flu is detected and identified using a variety of traditional and molecular diagnostic tools. Modern technology is able to diagnose influenza quite precisely and effectively.

For instance, the real-time molecular test known as the reverse transcription-polymerase chain reaction (RT-PCR) enables the detection of influenza genetic information.

Furthermore, due of its fast results and simple sample collection, rapid influenza diagnostics testing (RIDT) has evolved into an effective method for identification.

Flu prevalence is predicted to rise, early detection with particular diagnostic tests is becoming more popular, CLIA-waived POC molecular influenza assays are being produced, and the priority is shifting from controlled laboratories to distributed point-of-care testing has boosted the growth of the global influenza diagnostics market.

The global market is thus likely to show high growth over the coming years at a CAGR of 6.1% and reach a global market size of US$ 3.08 Bn by 2033.

Custom Report Cover

Make This Report Your Own

Take Advantage of Intelligence Tailored to your Business Objective

> Get a Customized Version

What Factors Will Drive the Market to Grow Over Forecast Period?

New Advancements in Diagnostic Tests for Influenza Infection

Quick reverse transcription polymerase chain reaction (RT-PCR), viral cultures, fluorescence assays, serological tests, antigen testing, and rapid molecular assays are some of the diagnostic tools available for influenza. However, due to their capacity to identify influenza viruses with low to medium sensitivity and a high specificity within 15 minutes, commercial rapid flu diagnostic tests are the most widely used approach for influenza detection.

Molecular diagnostic assays are a brand-new class of highly sensitive and specific molecular diagnostic tests for influenza that have emerged in recent years. The capacity to detect respiratory viruses has significantly improved thanks to the reverse transcription polymerase chain reaction (RT-PCR) and nucleic detection techniques.

The major goal of molecular tests for flu is to find specific known viruses utilizing nucleic acid amplification testing (NAT). NATs are preferable to other available diagnostic equipment in a variety of ways. They do not rely on the life of the intended bacterium and can produce results in a therapeutically appropriate amount of time. They may be able to identify low amounts of all known influenza viruses in clinical specimens.

Clinical research funding and expenditures in this field help to increase the scope of the projects that are done as well as the number of people engaged. Governments, the private sector, and businesses all provide money for research and development. For instance –

  • The Infection Control Clinical Research Consortium was announced by the Central Institute of Allergy and Diseases (NIAID) on December 19, 2019. For seven years, NIAID will provide financing for the Vaccine and Therapy Evaluation Units (VTEUs) initiative at a rate of about US$29 million annually.
  • The Collaboration Influenza Vaccine Innovations Centers (CIVICs) programme was launched by the Central Institute of Allergy and Infectious (NIAID), a division of the National Institutes of Health, on September 30, 2019. The initiative, which is intended to support CIVIC's programme centres over a seven-year period, receives roughly US$51 million in first-year funding from NIAID.
Market Research Methodology

Market Research Methodology

-Perfect through Years of Diligence

Check Research Methodology

Is there Any Impact on the Growth of the Influenza Diagnostics Market?

Lack of Skilled Labour & High Testing Costs”

Despite the fact that molecular diagnostic methods have become an essential component of research in the life sciences sector, a shortage of knowledgeable people and competent operators is expected to limit market growth. With the advent of technological and procedural advancements in biotechnology, the necessity for qualified professionals to perform molecular tests for disease diagnosis has become critical.

The market for influenza diagnostics, however, is constrained by the high price of molecular diagnostic procedures, reagents, and equipment. For instance, laboratories in developing nations like India and China cannot afford the expense of nucleic acid amplification and RT-PCR for the diagnosis of the influenza virus.

Commercial rapid flu tests are the most extensively used assays for influenza detection due to their speedy detection times. However, rapid diagnostic approaches for influenza are unable to identify influenza A viral subtypes. The RT-PCR and viral culture assays require several specimen types. Furthermore, when influenza activity is high, RIDT results are commonly misinterpreted as negative.

To validate negative test results, an expensive and time-consuming diagnostic tool, such as RT-PCR, viral culture, or others, is required. Furthermore, even when there is little flu activity, false positive results might occur.

RT-PCR also has technical concerns such as duplicated structures, reversed repeats, and a higher rate of sequence error. This increases the probability of false-positive pathogen detection results. Because DNA and RNA replication is so delicate and prone to contamination, false positive results are common.

Sales Team

Sales Team
Client Partner

Let's Connect

Connect me to identify winning opportunities

Ask An Expert
I'm Available

Country-wise Insights

Why is the U.S. Market Booming?

“Growing Influenza Have Started Adopting New Diagnostic Techniques”

The U.S. accounted for around 89.6% market share in the North America influenza diagnostics market in 2022.

The rising prevalence of influenza is expected to enhance the adoption of diagnostic kits in the country. The growing demand for more efficient medical procedures may result in new influenza diagnostic options. For example, the CDC estimated that there were between 4,700,000 and 7,900,000 flu cases reported in the United States between October 1, 2021 and April 16, 2022. Flu is the most commonly diagnosed condition in the U. S., and this aspect is expected to propel the market.

Another advantage to having well-known industrial firms in the country, such as Abbott and Quidel Corporation, is their engagement in the development and marketing of new products, which helps the U.S. market expand.

Will Germany Be a Lucrative Market for Influenza Diagnostics Manufacturers?

“New Innovative Kits by Key Players”

Germany holds a market share of around 35.3% in the global market, in 2022.

Germany is projected to dominate the regional market for rapid influenza diagnostic tests. This can be linked to a variety of factors, including an increase in the prevalence of influenza, supportive government interventions, the presence of important leaders, and advanced facilities throughout the country.

Furthermore, the existence of manufacturing facilities improves the country's access to influenza testing kits. Players are also collaborating on research studies to develop effective influenza diagnosis.

How is Japan Emerging as a Prominent Market for Influenza diagnostic?

“Increased Prevalence of Neurodegenerative Diseases”

Japan held a market share of about 45.2% of the East Asia influenza diagnostics market in 2022.

Because of its modern health care system, favourable legislation and insurance, numerous organisations, and several foreign enterprises, Japan is a thriving market for rapid influenza diagnostics testing. The advancement of research into influenza diagnostics technology is also closely related to the expansion of the country's market for these products.

The major drivers driving the market's expansion in Japan are an increase in influenza cases, a geriatric population, an increase in the requirement for rapid disease diagnostics, and a growing consolidation of top brands in the diagnostic business.

Category-wise Insights

Why is RT-PCR Becoming More Popular in Biological Research?

“Increasing New Testing Kits Will Ramp the Growth”

Molecular diagnostic tests held a global share of around 33.2% in the market in 2022.

In comparison to cell cultures, the RT-PCR approach yields findings in under 2 minutes. This approach is also useful for detecting antiviral resistance. These technological developments are expected to enable further market expansion.

Throughout the evaluation period, technological innovations are expected to continue driving market growth. Because of RIDTs' low sensitivity and inability to offer complete information on flu types and subtypes, RT-PCR analysis is expected to gain market share in the influenza diagnostics market. Many laboratories throughout the world have adopted RT-PCR as their go-to technique for diagnosing flu.

Thermo Fisher Scientific Inc., for example, offers a simple and easy-to-use RT-PCR with QuantStudio 3 and 5, which can be utilised by both novice and experienced users. With QuantStudio 3 and 5 RT-PCR, users can access and analyse their data remotely, as well as collaborate from any location via the Thermo Fisher Cloud.

Which Type of Flu Influences Market Growth?

“High Prevalence of Type A Flu”

Type A flu held a market share of around 39.1% in 2022.

The influenza A virus is responsible for the extremely contagious respiratory illness known as influenza (the flu). Type A influenza is a contagious viral infection that, if left untreated, can result in death. The diagnostic tools for influenza include immunofluorescence assays, viral culture, reverse transcription polymerase chain reaction (RT-PCR), serology, rapid antigen testing, and rapid molecular assays.

Type A flu is highly common in several countries, such as the U.S., and its increasing prevalence will continue to propel the growth of the overall market.

Which End User Offers the Global Market a Profitable Outlook?

“Growing Hospitals with Available Influenza Diagnostics Tests”

Hospitals held a share of around 53.9% in the global market, in 2022.

The growing number of hospitals and better awareness of influenza diagnostics have generated a profitable market expansion opportunity. The key motivator has been patients' demand for direct interactions with doctors in order to consult for optimal treatment and recover faster.

The market is expected to expand because to the increasing prevalence of infectious diseases and the increased use of rapid diagnostic testing equipment. As the number of influenza patients continues to rise, hospitals will accelerate overall growth, as well as the number of tests performed.

Competition Landscape

Mergers and acquisitions have emerged as one of the most important growth strategies employed by industry participants, taking into account global competition in the market. A number of well-known organizations are broadening their product lines with mergers as well as aquisitions, and partnering with both established and new markets.

Key instances include:

  • In March 2021, Roche, a pioneer in pharmaceuticals and diagnostics, purchased GenMark Diagnostics, Inc. for the sum of USD 1.8 billion. GenMark Diagnostics is a prominent provider of multiplex molecular diagnostic solutions. The acquisition will increase Roche's selection of molecular diagnostics.
  • Quidel Corporation stated in October 2020 that the USFDA would be marketing its SARS Antigen FIA + Sofia 2 Flu. This test uses the most recent immunofluorescence-based laterally flowing technology to provide a qualitative diagnosis of influenza A and B nucleocapsid protein. This approval aided Quidel Corporation in expanding its line of influenza diagnostics products.

Similarly, the team at Persistence Market Research has tracked recent developments related to companies in the influenza diagnostics market, which are available in the full report

Industry Report Scope



Forecast Period


Historical Data Available for


Market Analysis

USD Million for Value

Key Countries Covered

  • U.S.
  • Canada
  • Brazil
  • Argentina
  • Mexico
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Russia
  • India
  • Thailand
  • Malaysia
  • Indonesia
  • China
  • Japan
  • South Korea
  • Australia
  • New Zealand
  • Turkey
  • GCC
  • North Africa
  • South Africa

Key Market Segments Covered

  • Test
  • Type of Flu
  • End User
  • Region

Report Coverage

  • Market Forecast
  • Competition Intelligence
  • DROT Analysis
  • Market Dynamics and Challenges
  • Strategic Growth Initiatives

Key Companies’ Profile

  • Abbott Laboratories
  • Endress+Hauser (Analytik Jena AG)
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Inc
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic

Customization & Pricing

Available upon Request

Key Segments Covered in Influenza Diagnostics Industry Research


  • Molecular Diagnostic Test
    • RT-PCR
    • LAMP
    • NASABA
  • Traditional Diagnostic Test
    • Rapid Influenza Detection Test
    • Serological Assays
    • Direct Fluorescent Antibody
    • Viral Culture
    • H1N1 Influenza A Virus Identification Kits
    • Immunoassay Kits
    • Immunofluorescence Antibody Assay

Type of Flu:

  • Type A Flu
  • Type B Flu
  • Type C Flu

End User:

  • Hospitals
  • Diagnostic Laboratories
  • Research & Academic Institute
  • Contract Research Organization (CRO’s)


  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa

- Companies Covered in This Report -

  • Abbott Laboratories
  • Endress+Hauser (Analytik Jena AG)
  • Becton, Dickinson and Company
  • Biocartis
  • bioMérieux Inc
  • Danaher Corporation (Cepheid)
  • F. Hoffmann-La Roche Ltd
  • GenMark Diagnostics, Inc.
  • Luminex Corporation
  • Meridian Bioscience, Inc
  • Quidel Corporation
  • Thermo Fisher Scientific Inc.
  • Hologic

- Frequently Asked Questions -

The global market is expected to value at around US$ 1.7 Bn in 2023.

Sales of the market are set to witness growth, which is expected at a CAGR of 6.1% and be valued at around US$ 3.08 Bn by 2033.

Demand for the market increased at a 5.6% CAGR from 2015 to 2022.

U.S., Germany, Japan, China, & U.K. accounted for the major share in the global market as of year 2022, holding around 56.9% market share.

The U.S. accounts for around 89.6% regional share within the market in 2022.

China accounts for around 4.8% share of the global market in 2022.

Japan held a market share of about 45.2% of the East Asia influenza diagnostics market in 2022.

Germany held about 35.3% of the regional market share in year 2022.

Latin America is expected to expand at CAGR of 6.1% during the forecast period.

South Asia is expected to expand at CAGR of 7.9% during the forecast period.

This site uses cookies, including third-party cookies, that help us to provide and improve our services. Privacy Policy
Google translate